We are a global technology company providing the life sciences industry with solutions in big data analytics, management, visualization, and warehousing. Our offerings reduce risks, improve data quality, shorten time to market, and generate better insights from R&D and regulatory data.
Named to Gartners’ Cool Vendor List in 2013, PointCross is a leader in the life sciences industry and works closely with biopharma customers of all sizes across the globe including the FDA and 5 of the top 15 companies in pharma.
These core disciplines have driven PointCross into two areas of focus, Regulatory Submissions and R&D Drug Discovery.
We believe that the ideal drug discovery platform is not just be siloed to Nonclinical or Clinical, but would be translational. In addition, personalized medicine will have a large impact on how R&D is conducted. Deep informatics capabilities will be critical to biomarker success.
We also suspected the value of our R&D offerings increase with the adoption of machine readable standards for IND/NDA submissions. This drove our work with the FDA in setting the standards for Nonclinical regulatory submissions, the SEND standard. As this mandate goes into effect in December of 2016, our customers are positioned to easily implement one view across the complete drug discovery process.
The industry is seeing a surge of data being collected for each patient, including genomic data as a result of next generation sequencing. PointCross is now positioned to offer sophisticated correlative analysis of biomarker and genomic data to the efficacy and safety of drugs.